Ptc Therapeutics, Inc. Earnings

Ptc Therapeutics, Inc.’s revenue fell -4.19% since last year same period to $178.88Mn in the Q2 2025. On a quarterly growth basis, Ptc Therapeutics, Inc. has generated -84.79% fall in its revenue since last 3-months.

Ptc Therapeutics, Inc.’s net profit jumped 34.61% since last year same period to $-64.85Mn in the Q2 2025. On a quarterly growth basis, Ptc Therapeutics, Inc. has generated -107.48% fall in its net profits since last 3-months.

Ptc Therapeutics, Inc.’s net profit margin jumped 31.75% since last year same period to -36.25% in the Q2 2025. On a quarterly growth basis, Ptc Therapeutics, Inc. has generated -149.2% fall in its net profit margins since last 3-months.

Ptc Therapeutics, Inc.’s price-to-earnings ratio after this Q2 2025 earnings stands at 6.93.

Ptc Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -1.02 - a 3.77% jump from last quarter’s estimates.

Ptc Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -1.02.

Ptc Therapeutics, Inc.’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q3 2025. This indicates that the Ptc Therapeutics, Inc. has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.